Secondary outcome tests and questionnaires at follow-up
| Outcome | Intervention (n=65) | Control (n=80) | Treatment difference at FU (95% CI) | ||
| BL score | Δ with FU | BL score | Δ with FU | ||
| Trailmaking Test A, median (IQR) | 59.0 (36.9) | −8.4 (-4.8) | 61.0 (27.8) | −6.0 (1.6) | −0.01 (−0.11 to 0.09)* |
| Trailmaking Test B, median (IQR) | 149.0 (103.0) | −3.9 (24.1) | 152.0 (103.0) | 1.0 (19.0) | −0.01 (−0.14 to 0.11)* |
| DSST, mean (SD) | 36.4 (12.2) | 2.6 (1.2) | 36.4 (13.2) | 1.0 (-0.3) | 0.70 (0.11 to 1.30)*† |
| 7 MS enhanced cued recall, % (n) best scoring | 85 (55) | 0 (0) | 84 (71) | 5 (4) | 0.54 (0.15 to 1.90)‡ |
| 7 MS Benton temporal orientation, % (n) best scoring | 95 (62) | −3 (−2) | 99 (79) | −4 (−3) | 1.38 (0.28 to 6.88)‡ |
| 7 MS clock drawing, % (n) best scoring | 80 (52) | −8 (−5) | 86 (69) | −6 (−5) | 0.67 (0.28 to 1.62)‡ |
| 7 MS category fluency, mean (SD) | 16.1 (5.5) | 0.1 (−0.6) | 15.9 (5.0) | 0.4 (−0.3) | −0.18 (−1.55 to 1.20)* |
| GARS, % (n) best scoring | 72 (46) | 2 (−1) | 69 (54) | 0 (0) | 1.73 (0.62 to 4.84) ‡§ |
| Sedative side effects, median (IQR) | 3.0 (5.0) | −1.0 (-2.0) | 2.0 (4.0) | 1 (0) | 0.61 (0.40 to 0.94)¶† |
| UKU, median (IQR) | 17.0 (22.0) | −3.0 (1.0) | 18.0 (27.0) | −1.6 (−2.4) | 0.97 (0.67 to 1.39)¶ |
| EQ-5D-3L, % (n) best scoring | 74 (48) | 9 (6) | 76 (61) | 4 (3) | 1.43 (0.51 to 4.03)‡ |
| VAS, mean (SD) | 6.6 (1.6) | −0.2 (0.0) | 6.8 (1.4) | −0.1 (0.1) | −0.09 (−0.50 to 0.32)* |
| Up&Go, % (n) best scoring | 66 (42) | 0 (0) | 64 (50) | 4 (3) | 1.37 (0.60 to 3.14)ठ|
*Linear regression analysis (reporting unstandardised b).
†Statistically significant difference (p<0.05).
‡Logistic regression analysis (reporting OR).
§Deviation of number of patients: n=64 for intervention, n=78 for control, three patients were excluded from this test/questionnaire.
¶Negative binomial regression analysis (reporting incident rate ratio) used, all adjusted for age, gender, number of medication at baseline.
BL, baseline; FU, follow up, DSST, Digit Symbol Substitution Test; EQ-5D-3L, Euroqol-5 Dimension-3 Level; GARS, Groningen Activities Restriction Scale; UKU, Udvalg for Kliniske Undersogelser (measuring anticholinergic side effects); VAS, visual analogue scale (part of EQ-5D-3L); 7 MS, seven minute screen.